CTAD 2024 | Understanding agitation in Alzheimer’s disease and current approaches to management

Krista Lanctôt, PhD, Sunnybrook Research Institute, University of Toronto, Canada, speaks about agitation as a symptom of Alzheimer’s disease (AD) and current approaches for its management. She mentions that the prevalence of agitation increases as the disease progresses and is associated with a decreased quality of life and increased mortality. She goes on to speak about non-pharmacological interventions that are first-line treatment for agitation, followed by pharmacological interventions such as citalopram or atypical antipsychotics. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.